The Ningxia Hui Autonomous Region in China has launched 19 reform initiatives to deepen drug and device supervision and promote high-quality development in the pharmaceutical industry. The reforms focus on enhancing pharmaceutical quality, supporting research and development, optimizing review processes, innovating supervision methods, and improving regulations.

Key highlights include:

  • Comprehensive Reform Measures: 19 specific initiatives aimed at fostering pharmaceutical innovation and improving compliance and safety in both traditional and modern medicine.
  • Implementation Leadership: The Ningxia Food and Drug Administration will oversee the execution of these reforms to stimulate R&D and enhance drug and device research capabilities.
  • Focus Areas: Optimizing review processes, innovating supervision, supporting R&D, and improving regulatory frameworks to ensure higher quality and safety standards.

Freyr can help pharmaceutical companies navigate these reforms, align Regulatory strategies with China’s initiatives, and ensure compliance for successful market entry in China.

Consult Now

Select Mandate HA
NMPA
Select Mandate Function
Country Regulatory Affairs